Live Biotherapeutics Market

The live biotherapeutics market is poised for significant growth over the next decade. Starting from a valuation of US$105.5 million in 2023, the market is expected to experience a robust compound annual growth rate (CAGR) of 14% between 2024 and 2034. This rapid expansion is driven by increasing research and development in microbiome-based therapies, rising prevalence of chronic diseases, and growing awareness of the potential benefits of live biotherapeutics. Factors such as technological advancements in manufacturing and formulation, coupled with strategic collaborations and investments, are further fueling this positive trajectory.